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aa amino acid 
aaPG aminoacyl phosphatidylglycerol 
aaPL aminoacyl phospholipid 
aatRNA aminoacyl tRNA 
AlaPG alanyl phosphatidylglycerol 
AMS 4-Acetamido-4'-Maleimidylstilbene-2,2'-Disulfonic Acid 
AS Aminosäure bzw. Aminosäuren 
approx. approximately 
BM basic medium 
BSA bovine serum albumin 
β-ME β-mercaptoethanol (also 2-mercaptoethanol, 2-ME) 
C cysteine 
C. perfringens Clostridium perfringens 
ca. circa 
CAMP cationic antimicrobial peptide 
CM cell membrane 
C-terminus carboxyl-terminus 
CW cell wall 
D aspartic acid 
DAP daptomycin 
DAP-NS daptomycin nonsusceptibility / -nonsusceptible 
DAP-R daptomycin resistance /-resistant 
(synonym to DAP-NS) 
DAP-S daptomycin susceptibility /-susceptible 
DMSO dimethylsulfoxid 
DNA desoxyribonucleic acid 
dNTP desoxynucleotide triphosphates 
ECC electrocompetent cells 
E. coli Escherichia coli 
EDTA ethylendiaminetetraacetic acid 
EMA European Medicines Agency 
Etest Epsilometer test 
e.g. exempli gratia 
FDA Food and Drug Administration 
Fig. Figure 
HPLC high performance liquid chromatography 
IP buffer immunoprecipitation buffer 
KAMP kationisches antimikrobielles Peptid 
L. monocytogenes Listeria monocytogenes 
LB lysogeny broth 
LTA lipoteichoic acid 
LysPG lysyl phosphatidylglycerol 
MHB Mueller Hinton broth 
MIC minimum inhibitory concentration 
MOPS 3-(N-morpholino)propanesulfonic acid 
MPB N*-(3-Maleimidylpropionyl)Biocytin 
MprF multiple peptide resistance factor 
mRNA messenger RNA 
MRSA methicillin-resistant Staphylococcus aureus 
N-terminus amino-terminus 
ODλ optical density at wavelength λ (e.g. λ = 600 nm) 
O/N overnight 
P proline 
Pi Inorganic Phosphate 
PAGE polyacrylamide gel electrophoresis 
PB polymyxin B 
PCR polymerase chain reaction 
PE phosphatidylethanolamine 
PG phosphatidylglycerol 
PGS phosphatidylglycerol synthase 
PMSF phenylmethylsulfonyl fluoride 
polyp polyphosphate 
RNA ribonucleic acid 
RT room temperature (25 °C) 
S serine 
S. aureus Staphylococcus aureus 
SDM site directed mutagenesis 
SDS sodium dodecyl sulfate 




TBS tris-buffered saline 
TBST tris-buffered saline with Tween 
TFB1&2 transformation buffer 1&2 
TMD transmembrane domain 
TMS transmembrane segment 
Tris tris(hydroxymethyl)aminomethane 
tRNA transfer RNA 
TSB tryptic soy broth 
UPLC ultra performance liquid chromatography 
UV ultra violet 
VISA vancomycin-intermediate Staphylococcus aureus 
VRSA vancomycin-resistant Staphylococcus aureus 
WT wild type 




Staphylococcus aureus, first described in 1884 and named for being arranged 
in grape-like clusters (Greek σταφυλή (staphylé) – grape), round (Greek κόκκος 
(kókkos) – corn) and of yellow colour (Latin aureus – golden), belongs to 
facultative aerobic Gram-positive bacteria [58, 74]. As part of the flora and in 
30-50 % of mankind colonizing human nares, it is an opportunistic commensal 
and a major human pathogen [1, 15, 33, 91]. A diversity of diseases is caused 
by S. aureus, both community-acquired and nosocomial infections, e.g. skin and 
soft tissue infections, bacteraemia, infective endocarditis, pulmonary, catheter-
related, and osteoarticular bone and joint infections [3, 42, 80, 92]. To protect 
from such invasive infections, human evolution bore different mechanisms of 
the human innate immune system, such as cationic antimicrobial 
peptides (CAMPs) like defensins, bacteriolytic enzymes like lysozyme, and 
many more [48]. Defensins are mostly produced by neutrophils, and all three 
types of defensins (α, β, θ) mainly act via membrane permeabilisation, are 
active both intra- and extracellularly, and are chemoattractants for macrophages 
and neutrophils [26]. S. Aureus infections can be treated by an assortment of 
antibiotics with different targets, namely β-lactams (penicillins, cephalosporins 
and carbapenems), aminoglycosides, glycopeptides, sulfonamides, 
tetracyclines, and others [25, 51]. One of them is daptomycin (DAP), a cyclic 
lipopeptide antibiotic against Gram-positives with an anionic molecule core, 




Fig. 1: Structure of daptomycin showing the distribution of charge (colour coded). The structure was 
determined via nuclear magnetic resonance spectroscopy. Here, the anionic molecule core apo-daptomycin without 
Ca2+ is shown. Negative charge is indicated as red, neutral as white, and positive as blue. From Ball et al. [6]. 
On the one hand, DAP targets the cell membrane (CM) binding to 
phosphatidylglycerol and leading to membrane depolarisation due to a loss of 
cytoplasmic potassium ions, and, on the other hand, it interacts with proteins 
synthesising lipoteichoic acids (LTAs) and thereby inhibits cell wall (CW) 
synthesis [29, 37, 72, 82]. It is a last resort antibiotic, having gained approval in 
the US by the Food and Drug Agency (FDA) in 2003 and in Europe by the 
European Medicines Agency (EMA) in 2006 [46]. DAP offers an alternative 
therapy to vancomycin which has been the standard antibiotic of last resort for 
treatment of staphylococcal infections. Such alternatives become more and 
more necessary due to emergence of broad-spectrum antimicrobial resistant 
strains, such as in methicillin-resistant or vancomycin-intermediate S. aureus 
(MRSA, VISA) [16, 60]. In vivo, DAP resistance (DAP-R, synonym for DAP-NS, 
term for ease of presentation) has frequently been reported in recent years [9, 
19, 21, 24, 34, 37, 39, 44, 45, 57, 81, 94]. Bacteria can express a variety of 
resistance mechanisms to human CAMPs, for example (a) proteolytic 
degradation of CAMPs, (b) extracellular CAMP-capturing and -inactivating 
molecules, (c) active extrusion of CAMPs, and (d) reduction of the affinity of the 
bacterial cell envelope for CAMPs or repelling them via altering the bacterial 
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surface net charge, i.e. reducing or exchanging anionic charges of the cell 
surface and thereby neutralising the former negative net charge (Fig. 2) [67].  
 
Fig. 2: Bacterial resistance mechanisms against CAMPs. (a) Proteolytic degradation, (b) capturing and 
inactivating, (c) export, (d) altering the bacterial cell surface net charge and thereby reducing affinity, respectively, 
repelling. From Peschel et al. [67].  
Resistances as these, in turn, emerge upon genetic mutations [13, 17, 20, 68, 
69, 96]. Especially under selective pressure due to antibiotic treatment, as 
through vancomycin or daptomycin, such mutations can be – even 
simultaneously – induced via multiple evolutionary pathways, e. g. yccH and 
mprF, and are able to influence cross resistances to glycopeptides, such as 
vancomycin or teicoplanin [17, 22]. Nonetheless, resistances can occur at 
different genes leading to heteroresistances and do not have to be 
permanent [28, 43, 87]. A very blatant example is a reported evolution of a 
MRSA strain during a protracted clinical infection lasting 115 days. In one 
patient, diverse mutations appeared at different time points, and several 
different morphotypes with reduced antibiotic susceptibilities have been 
detected. After non selective growth, the genomes restored to their original 
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susceptibility profile [35]. There have been reports of MRSA strains 
spontaneously reverting to a subsequent methicillin-susceptible 
S. aureus (MSSA), and of DAP-NS MRSA strains having reverted to 
DAP-S [43]. Through discontinuation of the therapy with DAP a reversion of 
resistance was detected and the above mentioned enhanced findings 
decreased back to the same level as in DAP-S strains [43]. On the contrary, 
clinical DAP-NS strains have been described that did not revert their resistance 
and showed stable MICs even after two years of storage without DAP selective 
pressure [87]. Therefore, resistance proves to be a highly complex and 
multifaceted topic. 
Different DAP resistance mechanisms have been proposed. Most of them 
suggest alterations concerning different aspects of the cell wall, such as its 
composition, ionic charge and membrane fluidity [37]. While DAP-NS isolates 
can show more positive or similar charges of the cell surface as in DAP-S ones, 
DAP-NS is usually accompanied by higher thickness of the CW, higher mRNA 
levels (overexpression) of several two-component-systems (TCSs), higher 
amount of wall teichoic acids (WTAs), higher proportion of D-alanylated WTAs, 
and upregulated transcription of CW biosynthesis genes [14, 43]. In contrast, 
there is also data suggesting that DAP-R does not always correlate with positive 
net charge or thickness of the cell wall [61].  
Since CAMPs and numerous antibiotics target the bacterial membrane or have 
to pass it to take effect, both understanding interactions between CAMPs and 
the cell surface, and understanding the basic cell surface mechanisms is of 
great importance [2]. The bacterial cell surface is made up of a mesh of 
peptidoglycan teichoic acids that covers and spans out the lipid cell membrane. 
In many Gram-negative bacteria and only some Gram-positive bacilli the lipid 
membrane is composed of zwitterionic phosphatidyletholamine (PE), whereas 
several Gram-positive bacteria, like staphylococci, have mostly anionic 
phosphatidylglycerol (PG) and diphosphatidylglycerol (also known as 
cardiolipin, CL) [31, 70]. Moreover, numerous bacteria modify their membrane 
lipids with amino groups creating aminoacyl phospholipids (aaPL), in particular 
aminoacyl phosphatidylglycerols (aaPGs) as lysyl or alanyl phosphatidylglycerol 
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(LysPG, AlaPG). Addition of such amino acid (aa) moieties to membrane lipids 
increases the overall negative net charge of bacterial membranes by integrating 
cationic or zwitterionic charges. aaPLs are usually found in Gram-positives, 
especially LysPG which is synthesised by MprF proteins. While E. faecalis and 
other bacteria can have several types of aaPGs, in S. aureus there is only 
LysPG [4, 36, 67]. By converting PG to LysPG, the net charge of PG is changed 
from -1 to +1 [2]. Furthermore, as a major post-translational modification, 
N-succinyl-lysyl-PG has also been reported, which presumably forms a 
complete loop of charge reversal back to -1 [4]. The distribution and 
composition of phospholipids in the two leaflets of the membrane is not static 
but changes according to environmental challenges [48, 49]. Whereas in Gram-
negative bacteria, having an inner cytoplasmic membrane and an outer 
periplasmic membrane, some types of lipids are likely to be found exclusively 
within the outer compartment (Fig. 2 and 3) [55]. 
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Fig. 3: Chemical structures of the common phospholipids, PG and CL, and derived aaPG variants, changing 
their net charge from anionic to zwitterionic or cationic. R – residue, referring to the amino acid side chain. 
From Slavetinsky et al. [83]. 
Considering the alteration of the surface net charge as a resistance mechanism 
to CAMPs, there are two important and often described bacterial gene loci, the 
dlt operon and the multiple peptide resistance factor (mprF) [11, 18, 95]. 
The gene products of the dltABCD-operon are responsible for the D-alanylation 
of WTAs, resulting in a relatively increased net charge [95]. With the 
consequent altered electrostatic properties of the surface, the cell envelope is 
more tolerant to CAMPs [63, 95] and has reduced autolysis. Overexpression of 
dltA, which has been found in different strains, i. e. DAP-R clinical isolates or 
VISA [17, 18], resulted in reduced autolysis while biofilm formation remained 
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intact [63]. The overexpression of dltA is a common pathway of resistance, 
leading to an increase of D-alanylated WTA [18, 61]. Due to a point mutation in 
pitA (an inorganic phosphate transporter), the upregulation of the dlt operon is 
induced (not yet clear whether directly or indirectly) by intracellular 
accumulation of inorganic phosphate (Pi), while resistance is not triggered by 
the accumulation of polyphosphate (polyP), and the GraXRS TCS (an activator 
of the dlt operon and of mprF) is not involved [59]. In contrast, mutants lacking 
dlt gene products show increased affinity to CAMPs while the ability to bind to 
endothelial cells is decreased, leading to an attenuated virulence and reduced 
metastatic infections, although binding to fibronectin remains unchanged [95].  
In 2001, mprF was discovered as a gene locus in S. aureus which, when 
knocked out, led to high susceptibility of S. aureus to many CAMPs – hence the 
name ‘multiple peptide resistance factor’. It was shown that mprF knockout 
mutants, in comparison to the wildtype (WT), were killed significantly faster by 
neutrophils, had increased susceptibility to CAMPs, and possessed attenuated 
virulence in mouse and rabbit infection models. In one study, tested with one 
distinct type of human cells, MprF knockout mutants did not show reduced 
adherence to fibronectin and, in contrast to dltA knockout mutants, did not have 
a reduced binding to endothelial cells or reduced metastatic infections [66, 95]. 
Later, other species than S. aureus were found to have MprF homologues as 
well, with attenuated virulence when knockout mutants were tested [56, 90]. For 
instance, Bacillus anthracis gets hypersusceptible to CAMPs when mprF is 
knocked out due to impaired biosynthesis of LysPG [79]. Among prokaryotes, 
MprF and its nearly 350 known homologues, all being aminoacyl 
phosphatidylglycerol synthases (aaPGSs), belong to a highly conserved family 
of membrane proteins, which are found among 93 bacterial genera and three 
archaeal species [76, 77]. In S. aureus, MprF catalyses the synthesis of 
LysPG [66], and when trans-expressed in WT E. coli cells, LysPG synthesis can 
be detected [64]. The amount of aaPLs depends on environmental conditions 
and species, suggesting that biosynthesis of MprF is regulated [47, 56]. MprF 
regulation in S. aureus is conducted by the Aps/GraRSX TCS systems, which 
besides mprF activates other CAMP resistance genes such as the dlt operon, 
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when exposed to CAMPs [31, 52, 53]. A graS knockout mutant exhibits 
impaired mprF and dltA expression, resulting in increased sensitivity to CAMPs 
and DAP [23]. The expression of mprF can also be induced by antibiotics such 
as DAP [17]. Prolonged exposure to antibiotics such as DAP, vancomycin and 
telavancin were found to influence different gene regulations and expressions 
causing adaptations to the effects of glycol- and lipopeptide antibiotics [73]. The 
mprF gene has a length of 2520 base pairs and encodes a membrane protein 
consisting of 840 amino acids with a size of 93 kDa, forming twelve N-terminal 
transmembrane segments (TMSs) with an enlarged cytosolic loop between 
TMS 6 and 7, and a large cytosolic C-terminus (Fig. 4) [30, 83]. 
 
Fig. 4: Proposed topology model of MprF. Derived from a lysyl tRNA, the lysyl group (orange) is transferred to 
PG by the synthase domain. Translocation from the inner to the outer leaflet of the membrane of a LysPG is 
conducted via the flippase domain, building up a more positive net charge that repulses CAMPs. CAMP – cationic 
antimicrobial peptide, PG – phosphatidylglycerol, LysPG – lysyl PG. Modified after Slavetinsky et al. [83]. 
This large integral membrane protein possesses two distinct functions via its 
two separable functional sub-domains. One is the synthase domain, consisting 
of the large cytosolic C-terminus and the six C-terminal TMSs, producing LysPG 
in the inner leaflet of the bacterial cytoplasmic membrane. The other is the 
flippase domain, which is composed of the six N-terminal TMSs, translocating 
LysPG from inner to outer membrane leaflet, which is crucial for the resistance 
of S. aureus to CAMPs (Fig. 5) [2, 30, 83].  
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Fig. 5: Mode of S. aureus MprF-mediated bacterial resistance. From Ernst et al. [30]. 
The synthase domain acts uniquely like a transesterase, covalently linking a 
lysine residue derived from a lysyl tRNA to PG, hereby producing an aaPG [47, 
86]. The homologues of MprF can utilize different amino acid residues from 
different aminoacyl tRNAs (aatRNAs) to form different aaPGs [75]. Some MprF 
homologues possess a relaxed substrate specifity, such as E. faecalis MprF2 
which synthesises not only LysPG but also AlaPG and ArgPG, while these 
aminoacylations lead to increased resistances against CAMPs as well. Though, 
mprF1 from E. faecalis is not involved in that synthesis, only E. faecalis 
mprF2 [8, 83, 85]. Other homologues of MprF are restricted to only one type of 
aaPG, such as S. aureus specifically synthetizes LysPG [83, 85]. Furthermore, 
in Clostridium perfringens two homologues of MprF are encoded, one facilitating 
LysPG synthesis, the other one producing AlaPG. Although only the synthase 
domain for LysPG is fused to a flippase domain while the synthase domain for 
AlaPG is not, both LysPG and AlaPG can be translocated by the same flippase 
domain and confer CAMP resistance at a similar level. This resistance is 
achieved as long as the flippase domain and at least one of the two types of 
synthase are present. There is no need for both types of synthase to be present 
simultaneously. [84]. This indicates that MprF consists of two distinct and 
interacting synthase and flippase sub-domains, which both have to be present 
but do not have to be covalently linked for full MprF activity [31, 32].  
The membrane topology of MprF is not yet completely identified. Via X-ray 
crystallography, the structures of the cytosolic parts of the AlaPG synthase 
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domain (AlaPGS) from Pseudomonas aeruginosa MprF and of the LysPG 
synthase domain (LysPGS) from Bacillus licheniformis MprF were examined. It 
was displayed that the hydrophobic PG and the hydrophilic aatRNA opposingly 
access the catalytic site via a continuous tunnel. The main determinants to 
recognise the aaPG substrate have shown to be the tRNA acceptor stem, the 
aminoacyl moiety, and the hydrophilic head group of PG [40]. First assumptions 
about the topology of MprF had been made by the membrane protein topology 
prediction algorithm SOSUI [30]. Later, TOPCONS, another web server, was 
employed. The underlying algorithm of TOPCONS combines and quantifies 
topology predictions of five different algorithms in one consensus prediction, 
including OCTOPUS, a prediction method using a dataset of sequences with 
known and experimentally validated structures [12, 93]. In comparison, these 
predictions for the TMS topology of MprF by SOSUI and TOPCONS had 
essential differences from one another [32]. To reconnoitre the contrarieties, an 
experiment using marker enzymes had been conducted. Truncated variants of 
MprF were fused at several regions which were predicted loop regions to the 
marker enzymes galactosidase (LacZ) or alkaline phosphatase (PhoA). LacZ 
shows enzymatic activity only when it is in the cytoplasm. In opposition to that, 
intracellular PhoA is enzymatically inactive and shows activity only when 
translocated into the periplasm where intrachain disulphide bonds can be 
formed [32, 38]. These findings suggested that TOPCONS is superior to SOSUI 
considering predictions of the MprF membrane structure, as they were mostly 
conform to the prediction of TOPCONS, whilst it showed discrepancies to the 
prediction by SOSUI [32]. A research group around Andreas Peschel has 
created a monoclonal antibody which binds to that extended loop between 
TMS 6 and TMS 7 at amino acids 259 – 272. Originally, it was expected not to 
bind and thereby to confirm that the loop is cytoplasmic. But surprisingly, 
binding could be detected. In line with the results of an enzymatic experiment, 
data suggests that this loop can be both exposed to the cytoplasm and to the 
outer surface (Fig. 6) (Slavetinsky et al., unpublished). 
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Fig. 6: Comparison of the old and new topology analyses of MprF. Predicted MprF topology by SOSUI (top 
panel, labelled “old”) and actual topology based on the results of Ernst et al., largely following predictions by 
TOPCONS (bottom panel, labelled “new”). Determined activities of LacZ and PhoA via fusion constructs are 
displayed as red (LacZ) and blue (PhoA) asterisks. TMSs associated with the synthase domain are shown in dark 
grey, those with the flippase domain in light grey. Two putative α-helices as part of the extended loop are shown with 
dashed lines. The antibody’s specific binding to amino acids 259 – 272 within the extended loop (Slavetinsky et al., 
unpublished) is indicated as dashed arrow. Modified from Ernst et al. [32]. 
Therefore, it seems likely that in the course of flipping aaPGs from the inner to 
the outer leaflet of the bacterial membrane, this extended loop itself changes its 
location from intra- to extracellular, suggesting that this loop could possibly 
serve as an active enzymatic center, respectively, as a binding pocket.  
Better understanding of the MprF mechanism could be of great help, facing the 
increasing number of S. aureus strains that became spontaneously resistant to 
DAP during therapy, being thus resistant to virtually almost all available 
antibiotics [7, 62, 81, 94]. The adaptive mechanisms leading to DAP-R, at least 
partially, seem to be multi-factorial and strain specific [61]. Within those isolates 
showing spontaneous resistance, mutations in several genes (e. g. rpoB, rpoC, 
yycG, cls2, pgsA) and changes in the expression as well as mutations of 
dltABCD have been reported [7, 65]. Mutations of mprF (S295L, T345I), in turn, 
have been shown to play a role in an increased transcription of dltA [18]. In 
comparison to DAP-S MRSA, DAP-R MRSA strains have shown dysregulations 
of dltA and mprF, e. g. conferring an increased cell membrane fluidity or 
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reduced susceptibility to CAMPs [61]. There is a report of a clinical MRSA strain 
isolated from one patient during therapy, describing different genetic mutations. 
A mutation in rpoB led to a higher tolerance of DAP and other antibiotics due to 
pleiotropic changes conducting to a thicker CW but also less virulence traits and 
slower growth. Subsequently, loss-of-function of another locus, clpX, 
accelerated bacterial growth to some extent without effecting the susceptibility 
to antibiotics. Only after acquisition of a mutation in mprF, DAP-R was 
observed [5]. Other clinical DAP-R isolates lacking prior exposure to DAP and 
without mutations leading to amino acid substitutions in MprF have been 
reported [68]. Nonetheless, the major part of DAP-R S. aureus strains were 
found to have specific single nucleotide polymorphisms (SNPs) in mprF causing 
resistance to CAMP-like antibiotics, such as DAP [31]. Since mprF-knockout-
mutants lacking MprF are hypersusceptible to DAP, MprF itself is very unlikely 
to be the target of DAP [30]. Those point mutations leading to resistance occur 
within the open reading frame (ORF) of mprF and usually show a phenotype 
with gain-of-function considering either synthesis or flipping of LysPG, and a 
thicker cell wall, as electromagnetic and lipid membrane composition analyses 
revealed, while the SNPs appear to be not merely biomarkers but casually 
related to that phenotype. However, these findings have been merely shown in 
clinical isolates but not yet in a defined genetic background [61, 65, 97]. 
Different mprF mutations have been characterised for their effect on the 
phospholipid content and the proportion of LysPG to PG, and it has been shown 
that not all but some of them have effects on that content and that these effects 
differ from each other [78]. In clinical isolates of MRSA, there have been 
reported SNPs within the mprF in DAP-S strains, however, none of these SNPs 
were in the known hotspots for resistance to daptomycin but dispersed along 
the genome. In contrast, in DAP-R MRSA isolates, all SNPs were reported to be 
found in known hot spots (L341S or L826F). These isolates showed increased 
expression of mprF, gain-of-function of MprF, higher survival against CAMPs, 
and less binding of DAP to the cell membrane [10].  
The aims of this work are to further investigate the influence of the dlt operon 
and MprF on the bacterial resistance against CAMPs and CAMP-like antibiotics 
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such as DAP, to ultimately contribute to the better understanding of the 
mechanism of resistances via MprF, and to further explore the putative flipping 
mechanism of the large predicted intracellular loop within MprF. 
Bacterial resistance is based on a plethora of reasons and genes [13, 17, 20, 
68, 69, 96]. Amongst these, especially for DAP-R, mprF has been identified as 
the first genetic hotspot for mutations in clinical isolates or passage 
experiments [31]. These mutations occur mainly in the transition region from the 
synthase to the flippase domain. One of them is the missense mutation T345A 
associated with a DAP-R phenotype [62]. It shall be shown that the mediated 
resistance to DAP is operated via the cell wall. Therefore, the MICs, determined 
via Etest, of DAP have been compared to those of another antibiotic, bacitracin, 
which does not target the cell wall, in three strains of S. aureus Newman with 
the WT. The former is an anionic cyclic lipopeptide forming cationic complexes 
with calcium which mainly targets the CM and leads to its depolarisation [29, 37, 
41, 72, 82, 88]. The latter is a cyclic dodexylpeptide antibiotic impeding cell wall 
polymer biosynthesis due to inhibition of the dephosphorylation of undecaprenyl 
pyrophosphate (Upp) via the Upp phosphatase (UppP) which is required to 
recycle the lipid carrier [54, 71, 89]. When binding Upp, bacitracin completely 
envelopes the pyrophosphate group of the ligand [27].  
In a second step, it was examined whether DAP-R correlates with less binding 
of DAP to the CW. While it is known that in S. aureus, MprF serves as LysPGS 
and catalyses the synthesis of LysPG out of PG, the exact resistance 
mechanism to DAP is not clear [47, 66, 86]. Two major hypotheses have been 
suggested. One is that resistance to CAMPs and CAMP-likes is due to 
increased charge repulsion through positive charged LysPG. Other hypotheses 
consider that by synthesising more LysPG, there is less PG left for antibiotic 
agents targeting PG, such as DAP, to possibly interact with [83].  
Furthermore, having been involved in previous work from Sebastian Kuhn [50], 
other proteins of the synthesis apparatus of membrane lipids have been 
screened for steric closeness to MprF, implying possible interaction with MprF. 
The DltABCD system and MprF, respectively the overexpression of their genes, 
21 
are both common pathways of resistance [18, 61]. So another aim is to analyse 
the effects of those two resistance factors alone and in combination. 
Finally, as MprF’s structure and topology have been predicted by different 
software tools and, over the time, due to additional examinations and data these 
predictions had to be revised and adapted [12, 30, 32, 38, 40, 93], this work 
aims to investigate on this topic, namely, to show that there is a loop located 
both cyto- and periplasmic, indicating a flipping mechanism.  
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2 Material and Methods 
2.1 Material 
2.1.1 Primers and Sequencing 
PCR primers were synthesized by MWG-Biotech / Eurofins Genomics. The 
primer constructions were first checked for self-pairing or hybridization or 
hairpin formation via the free software “oligocalc”. 
DNA samples for sequencing were sent to GATC. 
2.1.2 Strains 
Table 1: Strains 
Species Strain Genotype / Characteristics Ref. 
Staphylococcus 
aureus 
Newman Wild type (WT)  
Staphylococcus 
aureus 
Newman ΔmprF Deletion of mprF.  
Staphylococcus 
aureus 
SA113 Wild type (WT)  
Staphylococcus 
aureus 







RN4220   
Escherichia coli BTH101   





Table 2: pRBs 
Plasmid Size 
[kb] 
Characteristics Host Resistance 
marker 
Ref. 








E. coli (100 µg/ml). 
[30] 








E. coli (100 µg/ml). 
[30] 












E. coli (100 µg/ml). 
 
pRB474mprF(syn) 7.6 Synthase domain of 
S. aureus MprF, 
reaching from aa 
274 – 840. 








E. coli (100 µg/ml). 
[30] 
pRB474cpmprF1 7.6 cpmprF1 of C. 
perfringens. 
AlaPGS. 








E. coli (100 µg/ml). 
[84] 




 in S. aureus 
(nn µg/ml). 
 
pTXdlt 11.4 dlt S. aureus,  
E. coli. 
  
pTX1-393 7.8 Plasmid with aa 1 
to 393 of mprF 
S. aureus,  
E. coli. 
  
pTX1-393(E206A) 7.8  S. aureus,  
E. coli. 
  
pTXYbhn 7.7  S. aureus,  
E. coli. 
  
pTXcpmprF2 8.4  S. aureus,  
E. coli. 
  
pT10 5.6 Empty plasmid. E. coli. Kan
R
 in E. coli 
(nn µg/ml). 
 
pT10mprF 7.8 mprF of S. aureus E. coli.   
pT10mprF(267) 7.8 mprF of S. aureus 
with a cysteine 
P267C 
E. coli.   
pT10mprF(267,731) 7.8 P267C, D731A E. coli.   
2.2 Culture media, growth conditions and strain maintenance 
2.2.1 Culture media 
Culture media were prepared with deionized water and autoclaved (20 min, 
2 bar, 120 °C). To prepare agar plates, agar (EU-Agar) was added to the 
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medium (15g / 1l) before autoclaving. For soft agar, a lesser amount of agar 
(4g / 1l) was used.  
Where required, antibiotics were added after autoclaving and after cooling down 
the medium to approx. 60°C. 
Basic medium (BM) 
 Caseinhydrolysate peptone 10 g 
 Yeast extract 5 g 
 NaCl 5 g 
 Glucose 1 g 
 K2HPO4 • 3 H2O 1 g 
 H2O ad 1 l 
 pH 7.2 
Luria Bertrani medium (LB) 
 Caseinhydrolysate peptone 10 g 
 Yeast extract 5 g 
 NaCl 5 g 
 H2O ad 1 l 
 pH 7.2 
Mueller Hinton Broth (MHB) 
 Cattle bouillon 2 g 
 Caseinhydrolysate peptone 17.5 g 
 Starch 1.5 g 
 H2O ad 1 l 
 pH 7.4 
Tryptic Soy Broth (TSB) and Casein-Soja-Pepton-Bouillon (CASO) 
 Casein peptone (enzymatic digest of casein) 17 g 
 Dipotassium hydrogen phosphate 2.5 g 
 Glucose (CASO contains no glucose) 2.5 g 
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 Sodium chloride 5 g 
 Soya peptone (enzymatic digest of soybean) 3 g 
 H2O ad 1 l 
 pH 7.2 
2.2.2 Growth conditions 
To grow cultures, appropriate media were chosen considering their 
requirements (i.e. strain, genotype, antibiotic resistance). For liquid cultures, 
depending on the volume needed, test tubes with 10 ml medium or Erlenmeyer 
flasks with e.g. 25 ml or 100 ml medium, were inoculated overnight (37°C, 
160rpm). These overnight starter cultures were generally used to inoculate main 
cultures to an initial OD600 0.1. 
Bacteria streaked on suitable agar plates were inoculated overnight in the 
incubator at 37°C. 
2.2.3 Strain maintenance 
Over short times (4-6 weeks), bacterial strains were kept on appropriate agar 
plates at 4°C. For long term storage, 1ml overnight culture was mixed with 1ml 
freez medium (65% glycerine; 0.1M MgSO4; 25mM Tris/HCl; pH 8) in a 
CryoTube and frozen at -80°C. 
2.3 Molecular genetic methods 
2.3.1 Isolation of plasmid DNA (Miniprep) 
For quick isolation of small amounts of plasmid DNA, the peqGOLD Plasmid 
Miniprep Kit I was used according to the manufacturer’s instructions. By doing 
so, the bacterial components get separated by silica columns: plasmid DNA is 
bound; unwanted proteins get eluted by different buffers. In the end, plasmid 
DNA is eluted with dd H2O or elution buffer (10 mM Tris-HCl, 0.5 mM EDTA, 
pH 9.0). 
Isolation of DNA from S. aureus include an extra lysis with lysostaphin which 
was added with Buffer P1 and incubated approx. 30min at 37°C to lyse more 
effectively. 
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2.3.2 Isolation of plasmid DNA (Midiprep) 
The Quiagen QIA Filter Plasmid Midiprep Kit was used to obtain higher 
amounts of plasmid DNA. The procedure is also based on alkaline lysis. 
2.3.3 Polymerase Chain Reaction (PCR) 
To synthesise specific short DNA sequences for the construction of plasmids, 
desired DNA fragments were amplified via Polymerase Chain Reaction (PCR). 
Therefore, a standardized approach and program was used varying the 
annealing temperature according to the congruence of the primers with the 
template, and the extension time according to length of the intended amplicon. 
For denaturation, the temperature required for the Phusion Hot Start 
Polymerase was used. 
Standard approach (total 50 µl) 
 H2O (bidest.) 37.5 µl 
 5 x Phusion HF reaction buffer 10 µl 
 dNTPs (10 mM of each dNTP) 1 µl 
 Primer 1 (10 pmol/µl) 2.5 µl 
 Primer 2 (10 pmol/µl) 2.5 µl 
 DNA template (genomic DNA 4 ng/µl) 1 µl 
 Phusion Hot Start Polymerase (2 U/µl) 0.5 µl 
Table 3: PCR programme 
Denaturation Denaturation Annealing Extension Final extension End
Cycles 1 1 -
Temp. 95°C 95°C 60°C 68°C 68°C 4°C





Generally, an annealing temperature of Tm ± 5°C was chosen. If the primers 
had a high tendency to hybridize and the PCR resulted in many unspecific PCR 
products, a higher annealing temperature was chosen. Lower annealing 
temperatures increased the output. 
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In this study, mostly lower temperatures were set. 
2.3.4 Site Directed Mutagenesis (SDM) 
By Site Directed Mutagenesis (SDM) point mutations can be inserted at defined 
locations in DNA molecules. This way, specific exchanges of base pairs 
resulted in an exchange of specific amino acids. Two complementary primers 
carrying the particular base pair to be exchanged were used to replicate whole 
double stranded (ds) plasmids via PCR. 
Standard approach 
 10 x reaction buffer 5 µl 
 dNTPs (10 mM of each dNTP) 1.5 µl 
 Primer 1 (125 ng) x µl 
 Primer 2 (125 ng) x µl 
 DNA template (plasmid DNA 5-10 ng) y µl 
 PfuUltra HF DNA polymerase (2.5 U/µl) 1 µl 
 H2O (bidest.) ad 50 µl total volume 
Table 4: PCR programme for SDM 
Denaturation Denaturation Annealing Extension Final extension End
Cycles 1 1 -
Temp. 95°C 95°C 60°C 68°C 68°C 4°C





Following the PCR standard approach, 1.5 µl of DpnI was added to the product 
and digested for 4-6 h at 37°C to remove template plasmids since they are 
methylated in contrast to the synthetic ones. The amplified plasmids were then 
transformed into chemically competent E. coli cells. 
2.3.5 Restriction digestion of DNA 
Each digest approach was adapted from the manufacturer’s advices as different 
restriction enzymes require different optimal conditions for full catalytic activity. 
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Standard approach (10 µl) 
 DNA sample x µl 
 10 x restriction buffer 1 µl 
 Restriction enzyme 0.5 – 1 µl 
 H2O (bidest.) ad 10 µl 
 
Digestions with ordinary restriction enzymes were incubated at 37 °C for 
approximately 6 h as 1 U enzyme is predicted to digest 1 µg DNA within an 
hour. To digest 1 µg DNA by “Fast digest” enzymes (Fermentas), DNA samples 
were incubated with 1 U recombinant enzymes at 37 °C for 10-15 min. 
For quality control of plasmids, “Fast digest” enzymes were used, and the 
product sizes were controlled via preparative agarose gel. 
2.3.6 Separation of DNA fragments via agarose gel electrophoresis 
Buffers and enzymes 
 50 x TAE buffer: 
2 M Tris/HCl; 0.1 M EDTA; 1 M acetic acid; pH 8.2 adjusted with glacial 
acetic acid; before use TAE buffer was diluted to 1-fold concentration (1 
x) with H2O (bidest.) 
 10 x Fast digest loading buffer 
 Agarose gel: 
0.5-1 % (w/v, according to requirements) agarose in 1 x TAE buffer 
 Size marker (1 kb ladder) 
 SYBR® Safe DNA gel stain solution (10 000-fold diluted) 
 Methylene blue (0.1 % in H2O) 
Agarose gels were prepared shortly before use (e.g. 1 g agarose in 100 ml 
1 x TAE buffer to get 1 % agarose gel). Gels with high percentage of agarose 
(up to 3 %) were used to separate smaller DNA fragments (200-1 000 bp). To 
separate larger fragments (6-10 kb) low percentage gels (< 1 %) were used. 
For the visualisation of DNA bands, SYBR® Safe was added 1 : 1 000 after 
cooling down below 60 °C (10 µl SYBR® Safe in 100 ml agarose gel) before 
pouring. Having applied a sample (10 : 1 mixed with 10 x loading buffer), the 
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electrophoresis was run with 140 V for 40 min and analysed with the gel 
documentation system BioDocAnalyse under photonic excitation at 
312 nm (UV). 
Electrophoresis of preparative gels ran with 140 V for 1-2 h. Then they first got 
stained with methylene blue for 10-20 min and afterwards destained with H2O 
(both shaking) until distinct bands were visible. On a light table, the desired 
band could be cut out. 
2.3.7 Extraction of DNA fragments from agarose gels 
For isolation of DNA fragments from agarose gels the peqGOLD Gel Extraction 
Kit was used according to the manufacturer’s instructions. The gel carrying the 
wanted DNA fragment was solubilised, and the DNA was isolated with a silica 
column. 
2.3.8 Purification of DNA after PCR or enzymatic modification 
With the aid of the peqGOLD Cycle-Pure Kit DNA was quickly purified from 
proteins and enzymes, according to the manufacturer’s advices. 
2.4 Transformation 
2.4.1 Heat shock transformation of of E. coli cells 
Preparation of chemically competent E. coli DH5α cells (for heat shock) 
Buffers and enzymes 
TFB1 buffer (pH 5.8): 
 RbCl 100 mM 
 MnCl2 50 mM 
 KC2O2H3 30 mM 
 CaCl2 10 mM 
 Glycerol 15 % 
TFB2 buffer (pH 8.0): 
 MOPS 10 mM 
 RbCl 10 mM 
30 
 CaCl2 75 mM 
 Glycerol 15 % 
Procedure 
1. Inoculate 100 ml LB with an O/N culture to an initial OD600 = 0.1, shake 
at 37 °C for approx. 2 h with 160 rpm. 
2. Transfer cells at OD600 = 0.5 in two sterile Falcon tubes (50 ml), incubate 
them briefly (5 min) on ice and pelletize them 10 min with 4600 rpm at 
4 °C 
3. Discard supernatant and keep the cells on ice 
4. Resuspend cells with cold (4 °C) TFB1 buffer (30 ml) and incubate for 
90 min on ice 
5. Pelletize cells (4600 rpm, 5 min, 4 °C) and discard supernatant 
6. Resuspend cells with cold (4 °C) TFB2 buffer (4 ml) 
7. Aliquot 100-200 µl of culture in sterile ERTs and store at -80 °C 
Heat shock transformation of competent E. coli DH5α 
Procedure 
1. Thaw 50 µl of competent E. coli DH5α cells on ice 
2. Place appropriate amounts of the ligation or SDM reaction mixture in 
ERT 
3. Add cells to DNA (up to 50 µl), mix gently and incubate for 15 min on ice 
4. Expose cells for 70-90 s to a heat shock at 42 °C in the Thermocycler 
5. Add 950 µl BM immediately and shake cells for 20-40 min at 37 °C for 
phenotypical expression of antibiotic resistance genes 
6. Plate culture on LB agar plates prepared with the appropriate selective 
antibiotic 
2.4.2 Electroporation of S. aureus cells 
Preparation of electrocompetent S. aureus 
Buffers and enzymes 
 Glycerine solution 10 % 
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Procedure 
1. Inoculate 100 ml LB with an O/N culture to an initial OD600 = 0.1, grow at 
37 °C for approx. 2 h in the shaker with 160 rpm. 
2. Transfer cells at OD600 = 0.5 into two sterile Falcon tubes (50 ml), 
incubate them briefly (5 min) on ice and pelletize them 10 min with 
4600 rpm at 4 °C 
3. From now on, work always on ice. Wash cells 3 times with 30 ml sterile, 
ice cold glycerine solution, pelletizing the cells after each washing step 
for 12 min with 4 600 rpm at 4 °C and discarding the supernatant 
4. Resuspend cells with 200 µl glycerine solution (v/v) per Falcon tube 
5. Aliquot 50 µl of cell suspension in ERTs and store at -80 °C 
Electroporation of competent S. aureus 
Procedure 
1. Thaw 50 µl of electrocompetent S. aureus cells at 4 °C 
2. Place appropriate amounts (2-10 µg) of plasmid in ERT (do not exceed a 
volume of 50 µl H2O with plasmids) 
3. Add cells to DNA, mix gently and incubate for 30 min at RT (25 °C) 
4. Transfer DNA cell mixture in a electroporation cuvette (0.2 cm cuvette) 
5. Adjust Eppendorf Multiporation apparatus and electroporate with the 
following conditions: 
Pulse: U = 2.0 kV; C = 25 µF; R = 100 Ω 
Optimal time constant: 2.5 ms 
6. Add 950 µl BM immediately and shake cells for 1.5-2 h at 37 °C for 
phenotypical expression of antibiotic resistance genes 
7. Plate approach on BM or TSB agar plates with the appropriate antibiotic 
and incubate overnight at 37 °C 
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2.5 Transduction 
2.5.1 Propagation of phage 
Solid propagation of phage Φ11 
Buffers and enzymes 
 BM soft agar 
Procedure 
1. Dilute a fresh O/N culture of the propagation strain (RN4220 for Φ11) to 
OD600 = 0.1 and transfer 90 µl into a 15 ml Falcon tube 
2. Add 1 ml of the phage lysate to be propagated 
3. Incubate for 5 to 10 min at RT (25 °C) 
4. Add 5 ml BM soft agar pre-warmed to 47 to 49 °C 
5. Several times (3 - 5 x), vortex thoroughly and invert 
6. Plate mixture on TSA plate avoiding bubbles, incubate O/N at 37 °C; the 
next day, there should not be seen any CFUs, but if so, less propagation 
strain is necessary 
7. Carefully, scratch off the soft layer into a 50 ml Falcon tube, wash the 
plate with 1 ml TSB and add it carefully into the tube 
8. Centrifuge for 10 min with 4 600 rpm at RT, transfer the supernatant into 
a 1.5 ml ERT 
9. Centrifuge for 10 min with 13 000 rpm, transfer supernatant in fresh ERT 
10. Store propagated phage lysate at 4 °C 
Liquid propagation of Φ11 
Buffers and enzymes 
 CaCl2 stock solution 
Procedure 
1. Dilute a fresh O/N culture of the propagation strain (RN4220 for Φ11) 
with BM to OD600 = 0.1 and transfer 100 µl into a 15 ml Falcon tube 
2. Add 2 ml of the phage lysate to be propagated (Vphage) 
3. Add 3 ml BM (VBM) 
(when dealing with higher volumes, VBM should not exceed Vphage) 
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4. Add sterile CaCl2 solution to a final concentration of 4 mM 
5. Incubate with shaking for 3 h at 37 °C, until mixture is clear 
6. Centrifuge in ERTs for 10 min with 13 000 rpm 
7. Sterile filter the supernatant to a fresh Falcon tube 
8. Store at 4 °C 
Spot assay for quantifying phage concentration 
Buffers and enzymes 
 BM soft agar 
Procedure 
1. Dilute a fresh O/N culture of the propagation strain (RN4220 for Φ11) 
with BM to OD600 = 0.1 and transfer 100 µl into 5 ml BM soft agar;  
the soft agar should be previously melted and used at approx. 50 °C 
2. Pour the bacteria-containing soft agar onto a BM agar plate, leave it for 
5 min 
3. Prepare a serial dilution of the phage lysate in BM up to 10-8 
4. Spot 10 µl of each dilution onto the plate in a distinct pattern 
5. Incubate the plate O/N at 37 °C facing up 
6. Count spots (n), multiply by 102 as for getting from 10 µl to the 
concentration per ml, multiply by 10|x|, with x being the exponent of the 
step of dilution the spots are counted in: 





a good titre should be between 109 and 1011 
2.5.2 Phage transduction 
Buffers and enzymes 
 CaCl2 stock solution 400 mM 
 Phage buffer 
o CaCl2 4 mM 
o MgSO4 1 mM 
o Tris-HCl pH 7.8 50 mM 
o NaCl 100 mM 
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o Gelatine 0.1% 
→ Autoclave 
Procedure 
1. To load the phage with plasmid of a donor strain, dilute a fresh O/N 
culture of the donor strain to OD600 ≈ 0.5 in phage lysate to a final volume 
of 1 ml, add CaCl2 to a final concentration of 4 mM (i. e. 10 µl stock 
solution) 
2. Incubate for 30 min at 37 °C without shaking, then 
incubate for 3 h at 30 °C with low agitation (Thermomix 300 rpm) 
3. Centrifuge for 10 min at 5 000 g, sterile filter (0.2 µm) the supernatant; 
if necessary, store at 4 °C 
4. Dilute a fresh O/N culture of the recipient strain to OD600 ≈ 0.5 in BM 
5. Pelletize 200 µl, resuspend the pellet in 200 µl Phage buffer, add 100 µl 
of the loaded phage lysate 
6. Incubate for 15 min at 37 °C with slight agitation (Thermomix 300 rpm) 
7. Plate onto TSA agar plates prepared with the selective antibiotic of the 
plasmid (Clarithromycin for pRB, and Spectromycin according to the 
resistance gene within the gene cassette of S. aureus SA113ΔdltA) 
8. Incubate O/N at 37 °C 
2.6 PC based sequence analysing methods 
2.6.1 Sequence analysis 
Sequences of nucleic acids or proteins were analysed with SeqBuilder 
(Lasergene 7 of DNASTAR). Thereby, sequence alignments, primer 
constructions and control of GATC sequences could be performed. BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to analyse complete genome 
sequences. 
2.6.2 Data analysis, creation of diagrams and pictures 
Data was analysed via GraphPad Prism 7, where mentioned, unpaired t tests 
were carried out, figures were edited with Adobe Photoshop CC 2014. 
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2.7 Analytical methods  
2.7.1 Determination of susceptibility to antimicrobial peptides 
In order to determine how susceptible the different strains are to antimicrobial 
peptides, the MICs of some specific antimicrobial agents were identified via the 
Epsilometer test (Etest). The MIC describes the lowest concentration of an 
antibiotic to prevent visible growth of a microorganism after being incubated 
overnight. Strains, at a defined OD600 plated on an agar plate to gain a bacterial 
lawn, were exposed to different specific concentrations of antimicrobials, 
incubated overnight (20-22 h) and their growth examined. All working steps 
occurred under sterile conditions. 
Determination of MICs via Etest 
Buffers and enzymes 
 MHB 
 MHB agar plates with appropriate induction source (e.g. 0.5 % xylose) 
 Etest stripes 
Procedure 
1. Adjust 1 500 µl of a fresh overnight culture to OD600 = 0.05 in a 2 ml 
ERT: Measure the OD600 of the O/N culture and dilute appropriately with 
medium (MHB without antibiotics) 
2. Dip a sterile cotton swab into the ERT for approx. 20 s, carefully twirling 
until enough culture is absorbed 
3. Smear the culture onto MHB agar plates: first do three diameter like 
strokes in different directions (usually ca. 0°, 45°, 90°), then spread them 
smearing orthogonally to each of them until the plate is completely 
covered with bacteria and not wet anymore 
4. Carefully place an Etest stripe onto the plate, avoid pressure or shifting 
5. Turn the plate upside down and incubate for 20-22 h at 37 °C 
2.7.2 Determination of daptomycin binding via UPLC 
To determine how much Daptomycin binds to the bacterial surface of different 
strains, different amounts of bacteria were required. Bacteria loads were quite 
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high, as on the one hand very little Daptomycin binds to the surface and on the 
other hand a possible difference needs to be large enough to be clearly 
detectable by UPLC. Those high density cultures were incubated with a specific 
amount of Daptomycin (i.e. specific volume with specific concentration). 
Analysing the supernatant for free Daptomycin (“left-over”) allows the 
calculation of the amount of Daptomycin bound. 
Preparing for UPLC 
Buffers and enzymes 
 MHB BD + 50 µg Ca2+/ml 
 Daptomycin stock solution 200 µg/ml 
Procedure 
1. With an O/N culture (20 ml MHB), inoculate a main culture to OD600 = 0.1 
in 250 ml MHB without supplements and incubate with shaking at 37 °C 
until reaching 0.7 < OD600 < 1.0 
2. Pelletize the cells 15 min, 4 000 rpm, RT (25 °C) 
3. Resuspend pellet in 1 ml MHB BD supplemented with 50 µg Ca2+/ml 
4. Measure OD600 (therefore, dilute 10 µl in 990 µl MHB, take 100 µl of that 
and dilute with 900 µl MHB) 
5. Adjust 600 µl to OD600 = 200 in an ERT (2 ml) 
6. Make a serial dilution with n dilutions (here n = 3 for OD600 = {200; 100; 
50; 25} 
a. Provide n ERTs (2 ml) with 300 µl MHB BD + 50 µg Ca2+/ml 
b. Transfer 300 µl of the suspension into the first ERT, mix 
thoroughly 
c. Transfer 300 µl of ERT no. (n-1) into no. (n), mix thoroughly, 
take out and discard 300 µl 
d. Transfer 200 µl each into a fresh ERT (1.5 ml) 
7. Prepare standard: 2 ERTs (1.5 ml) with 200 µl MHB BD + 50 µg Ca2+/ml 
8. Incubate 15 min, 37 °C, 400 rpm in the Thermocycler 
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9. Add Daptomycin to a resulting concentration of 100 µg/ml 
Stock solution: c = 200 µg/ml => 200 µl added 
Finally resulting OD600 = {100; 50; 25; 12.5} 
10. Incubate 10 min, 37 °C, 400 rpm 
11. Pelletize the cells: 12 min, 14 000 rpm, RT (25 °C) 
12. Sterile filter the supernatant (here used 0.2 µm) 
13. UPLC 
2.7.3 Labelling single cysteine in loops of transmembrane proteins 
To determine the position of a specific domain of MprF, a single cysteine was 
inserted via SDM. E. coli or S. aureus cultures (in 50 ml LB or BM with 
supplements added if needed for induction of the plasmid, e. g. rhamnose for 
pT10) were grown to the exponential phase (OD600 = 0.5). The culture was 
divided in 2 aliquots, pelletized, and resuspended in Buffer A. For one part, the 
extracellular side was labelled with MPB (700 µl suspension + 7.5 µl 10 mM 
MPB adds up to a final concentration of approx. 0.1 mM MPB), the other half 
was blocked with AMS. After bead milling, the first half was left unprocessed, 
the other half labelled on the cytoplasmic side with MPB. The supernatants 
were pelletized via ultracentrifugation at 38 000 x g. 
With these an immunoprecipitation was performed to extract the FLAG-tagged 
proteins containing the single cysteine with the aid of magnetic FLAG beads. 
These were separated by SDS PAGE and visualised via Western Blot by using 
three antibodies (Streptavidin 800nm + anti-FLAG; anti-mouse 700nm). The 
proteins were detected with LICOR (using two channels, 700 nm and 800 nm). 
 
Buffers and enzymes 
 N*-(3-Maleimidylpropionyl)Biocytin (MPB) 10 mM in DMSO 
 4-Acetamino-4‘-Maleimidylstilbene-2,2’-Disulfonic Acid (AMS) 20mM in 
DMSO 
 Buffer A (best, if already high-conc. stock solutions there to mix) 
o HEPES 100 mM 
o Sucrose 250 mM 
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o MgCl2 25 mM 
o KCl 0.1 mM 
→ pH 7.5 with KOH (ca. 6 ml) 
→ sterile filter, store at 4 °C 
 IP buffer 1 / 2 
o Tris-HCl 50 mM 
o NaCl 150 mM / 1 mM 
o EDTA 1 mM 
o Thesit 2 % 
o SDS 0.4 % 
→ pH 8.1 with HCl 
→ sterile filter, store at 4 °C 
 Solubilisation buffer 
o Tris-HCl 50 mM 
o EDTA 1 mM 
o SDS 2 % 
 Rhamnose 100 mM 
 MgSO4 1 M (or MgCl2) 
 EDTA 0.5 M, pH 7.5 
 β-ME 2 M (β-Mercaptoethanol) 
 Glycin HCl 0.1 M, pH 2.2 
 Tris-HCl 1 M, pH 9 
 PMSF 50 mM in isopropanol (Phenylmethylsulfonyl fluoride) 
Main culture and labelling 
1. With an O/N culture, inoculate  
50 ml LB + Rha 100 µM (for E. coli) or BM (for S. aureus) + AB; 
Incubate at 37 °C to OD600 ≈ 0.5 (if too much degradation, 30°C) 
2. After this step, work always on ice. 
Pelletize cells in two Falcon tubes (50 ml, containing each 25 ml culture) 
(Meanwhile the glass beads for step 6 can be prepared) 
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3. Resuspend in 700 µl Buffer A supplemented with MgSO4 (to 1 mM, or 
MgCl2), lysozyme, protease inhibitor, DNase, EDTA (to 1 mM), pH 7.5; 
Do this carefully, avoid bubbles (they would damage the membrane) 
4. Incubate 30 – 60 min on ice 
5. Labelling / Blocking extracellular 
a. Labelling extracellular: 
add 7.5 µl MPB (10 mM); incubate 20 min;  
quench reaction by adding 7.5 µl β-ME (2 M) 
b. Blocking extracellular: 
add 3.75 µl AMS (20 mM); incubate 20 min; 
do not quench reaction 
6. Add samples to 0.5 ml pre-cooled glass beads in 1.5 ml screw cap tubes 
7. Labelling cytoplasm 
a. Not labelling cytoplasm (having labelled extracellular): 
- 
bead mill for 30 s with 6 m/s 
- 
b. Labelling cytoplasm (steps should be done within 2 min): 
add 7.5 µl MPB (10 mM); 
bead mill for 30 s with 6 m/s; 
quench reaction after max. 2 min by adding 7.5 µl β-ME (2 M) 
8. Centrifuge 1 min, 1 000 x g, 4 °C; 
transfer supernatants into fresh ERTs (1.5 ml),  
avoid taking out beads as much as possible 
9. Centrifuge 2 min, 10 000 x g, 4 °C 
transfer equal volumes (e.g. 450 µl) supernatant into ultracentrifugation 
tubes (1.5 ml), (leave 1-2 mm in ERTs to be sure of not carrying beads); 
make sure to have exact the same amount in every ultracentrifugation 
tube; 
tare tubes on precision scale 
10. Ultracentrifuge 30 min, 38 000 x g, 4 °C 
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11. Aspirate supernatant with (vacuum) pipet; 
pellet should be mostly yellow/translucent, few black dots are okay; 
if pellet is big and mostly white, steps 9-10 should be performed more 
carefully next time 
12. Freeze pellet at -80 °C (-20 °C is sufficient only if proceeding the next 
day) 
Immunoprecipitation (IP) 
1. Thaw samples on ice (1 h; 30  min is enough if from -20 °C) 
2. Add 100 µl buffer A pH 7.5 supplemented with β-ME (to 0.02 M); vortex 
1 h, 1 400 rpm, 4 °C (meanwhile you can prepare magnetic FLAG beads 
as in step 7) 
3. Add 100 µl solubilisation buffer, vortex 30 min, 1 400 rpm, 4 °C 
4. Keep at 37 °C for 30 min 
5. Vortex 30 min, 1 400 rpm, 4 °C 
6. Add 300 µl IP buffer 1; centrifuge 10 min, max speed, 4 °C 
7. Prepare magnetic FLAG beads (keep beads and rack on ice): 
a. Take a total of 5 µl FLAG bead slurry per sample;  
pipette slowly, leave tip in slurry and stir 
b. Pipette into ERT (1.5 ml) inserted to magnetic rack (or hold a 
magnet to the ERT), angle tip, so beads are pulled out, take off 
liquid 
c. Wash 2 x with twice as much volume of IP buffer as slurry 
d. Take off buffer, add half as much volume of IP buffer 1 as slurry 
e. Put 5 µl per sample into ERTs (1.5 ml) on magnetic rack, angle 
tip, so beads are pulled out; take tubes out of magnetic rack (or 
put magnet away) 
8. Add supernatant from step 6 onto prepared magnetic beads in ERTs 
(1.5 ml); 
incubate 1-2 h rotating at 4 °C 
9. Wash 3 x with 100 µl IP buffer (last time with IP 2); 
make sure to take tubes out of the rack and rinse the beads off the wall; 
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leave beads 5 min in IP buffer before removing it again; 
get as much buffer as possible off after last washing step; take tubes out 
of magnetic rack 
10. Elution: add 50 µl glycine HCl (0.1 M, pH 2.2 or 3.5); 
incubate 15 min at RT (25 °C, possibly Thermocycler with minimum 
shaking); 
if degradation, lower temperature (to 10 or 4 °C) 
11. Prepare ERTs (1.5 ml) with 3 µl Tris-HCl (1 M, pH 9) 
(later, if the stains on the preparative gel are blue, this step was done 
alright; 
later, if the stains are yellow, probably the mixture got too acidic in this 
step) 
Transfer 40 µl eluate to prepared tubes; add 10 µl SDS buffer; 
12. if necessary, store at 4 °C 
SDS PAGE 
Buffers and enzymes 
 5 x SDS sample buffer (250 mM Tris-HCl, pH 6.8, 10% SDS, 
30% (v/v) Glycerol, 10 mM DTT, 0.05% (w/v) Bromophenol Blue) 
Procedure 
1. Pipette 20 µl of the sample and 5 µl 5 x SDS sample buffer into an ERT 
(1.5 ml)  
and incubate 5 min at 37 °C 
2. Apply 10 µl onto a 10 % SDS gel 
3. Start electrophoresis for 15 min with 20 mA,  
then increase to 40 mA for 30-60 min 
Western Blot 
Buffers and enzymes 
 10 x Towbin buffer 
o Trizmabase 250 mM 
o Glycin 1 920 mM 
42 
→ pH should be 8.3 (do not adjust) 
o SDS 3.7 g/l (wear mask, stir slowly to avoid bubbles) 
 1 x Towbin buffer 
o 10 x Towbin 1:10 
o H2O 7:10 (before Methanol to avoid precipitating) 
o Methanol 2:10 
 10 x TBS 
o Trizmabase 500 mM 
o NaCl 1 500 mM 
→ pH 7.5 with HCl 
 1 x TBS 
 1 x TBST 
o Tween 0.05 % 
 1 x TBST + 3 % BSA (0.3 g for 10 ml) 
 
Antibodies 
1. Streptavidin 800 1:10 1000 + anti-FLAG 1:10 1000 (each 1 µl in 10 ml 
TBST)  
2. anti-mouse 700 1:10 000 (1 µl in 10 ml TBST) 
 
Procedure 
1. Activate membrane (Immobilion FLPVDF), for each side 10 s by 
immersion in methanol; then put in an extra box with Towbin buffer 
2. Layer (from white bottom to black top): 
1. Sponge soaked in 1 x Towbin buffer 
2. Whatman paper 5 mm soaked in 1 x Towbin buffer 
3. Activated membrane, add some 1 x Towbin buffer 
4. SDS gel (incubated in 1 x Towbin buffer) 
5. Whatman paper soaked in 1 x Towbin buffer, roll out bubbles with test 
tube 
6. Sponge soaked in 1 x Towbin buffer, add some 1 x Towbin buffer on 
top 
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3. Blotting: 1 h, 15 V 
4. Take off gel (should be empty) 
5. Block: Incubate membrane in lightproof or dark box with 1 x TBST + 
3 % BSA (do not use milk) for 1 h 
6. Wash 2-3 x 5 min with 1 x TBST 
7. Incubate 1 h with 1st antibody: 
Streptavidin 800 1:10 000 + anti-FLAG 1:10 000 (each 1 µ in 10 ml 
TBST) 
8. Wash 3 x 5 min with 1 x TBST 
9. Incubate with 2nd antibody: anti-mouse 700 1:10 000 (1 µl in 10 ml TBST) 
10. Wash 1-2 x 5 min with 1 x TBS (not TBST) 
 Visualise Membrane with the Odyssey Imaging System of LI-COR 
(Lambda Instruments Corporation): 2 channels, 700 and 800 nm  
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3 Results 
3.1 Comparison of daptomycin binding to S. aureus 
3.1.1 Daptomycin susceptibility of S. aureus knockout mutants 
The main objective of this experiment was to compare the effects of the point 
mutation T345A to the WT in regards to their antibiotic susceptibility.  
For this, the MICs of two antibiotics, daptomycin and bacitracin, were 
measured (see 2.7.1). The following five stems were used: (a) the WT, (b) the 
mprF-knockout-mutant, (c) knockout mutants with the plasmid pRB being 
empty, (d) pRB containing mprF as complementation, and (e) pRB containing 
mprF with the DAP-R point mutation T345A leading to DAP resistance. 
The mprF knockout mutant bearing the empty vector plasmid pRB showed the 
same susceptibility to both antibiotics as the mprF knockout-mutant without 
plasmid. Complemented with pRBmprF, the MICs of both antibiotics were on 
the level of the WT. Mutants bearing the missense mutation T345A, however, 
tolerated much higher concentrations of DAP, while susceptibility to bacitracin 
was not altered. This shows the point mutation T345A mediates resistance 
specifically against DAP. Furthermore, it implies that the mechanism of 




Fig. 7: MICs of DAP and bacitracin (a, b) for five strains of S. aureus Newman: WT (1), mprF-knockout-
mutant (2), the knockout mutant with an empty plasmid (3), the knockout mutant complemented (4), and the 
knockout mutant complemented with the DAP-R mutation T345A (5). Biological replicates n = 4. P values of 
unpaird t tests are: a.1 vs. a.2 0,0473; a.1 vs. a.4 0,1396; a.1 vs. a.5 0,0002; b.1 vs. b.2 0,0004; b.1 vs. b.4 0,2528; 
b.1 vs. b.5 0,0005. 
3.1.2 Quantitative determination of daptomycin binding to S. aureus via HPLC 
In order to analyse binding of DAP to S. aureus in DAP-S versus DAP-R strains, 
the quantity of DAP in the supernatant of strains with different genotypes 
(knockout, complementation, resistance mutation T345A) was analysed via 
UPLC after a defined incubation of DAP with respective strains in medium 
endued with Calcium (see 2.7.2). The different concentrations of the bacterial 
suspensions were adjusted based on their CFUs, specifically their OD600. Then 
they were incubated with a specific amount of DAP and Calcium for a defined 
time. Finally, free DAP released to the supernatant was quantified. The 
difference of DAP before and after incubation was assumed to be the portion of 
DAP bound to the cell surface. 
The results showed that the less bacteria in suspension are exposed to DAP, 
the higher is the concentration of free DAP, suggesting that the binding is 
proportional to the amount of bacteria. However, no difference could be seen 
when comparing the complementation with native mprF and the mutant 
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mprF345. In fact and contrary to expectations, the mprF knockout mutant and 
its complementation did not seem to differ in DAP binding neither. 
 
Fig. 8: Percentage of cell-bound DAP to different strains determined via UPLC. Three strains of S. aureus 
mprF-knockout mutants with (a) the blank pRB, (b) the complementation pRBmprF, and (c) the resistance mutation 
pRBmprF345 each in condensed suspensions with final ODs600 of 100, 50, 25, and 12.5 (a.1 – a.4, b.1 –b .4, c.1 –c.4) 
were incubated with DAP and Ca2+. Via UPLC, the supernatant was analysed for DAP. The differences of the 
concentrations of DAP before and after incubation was interpreted as DAP bound to the bacteria. Biological 
replicates n = 8. P values of unpaired t tests are: a.1 vs. a.2 0,6040; a.1 vs. a.3 0,0066; a.1. vs. a.4 0,0006; 
a.1 vs. b.1 0,6040; a.2 vs. b.2 0,5547; a.3 vs. b.3 0,4798; a.4 vs. b.4 0,9771; a.1 vs. c.1 0,3486; a.2 vs. c.2 0,0905; 
a.3 vs. c.3 0,7557; a.4 vs. c.4 0,7342. 
Therefore, it can be confirmed that daptomycin binds to the cell surface. 
However, there seems to be no difference in DAP binding, whether MprF is 
present or not. Consequently, it seems unlikey that the resistance mechanism 
of MprF is based on charge repulsion. Likewise, the DAP-R mutation SNP 
T345A in mprF does not lead to an increased repulsion of DAP into the 
supernatant, which suggests that the increase in DAP-R via the SNP T345A is 
due to another effect. 
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3.2 Analysis of an assumed interaction between DltABCD and MprF 
3.2.1 Screening for interactions between MprF and other proteins of the synthesis 
apparatus for membrane lipids 
A screening using the bacterial adenylate cyclase two-hybrid (BACTH) method 
was performed to show steric closeness and to find interaction partners for 
MprF among proteins of the LTA synthesis machinery. Transformed E. coli 
BTH101 with constructs expressing MprF fused to the T18 fragment of the 
adenylate cyclase, and proteins from the LTA synthesis machinery (DltA, DltB, 
DltC, DltD – D-alanylation of polyanionic cell walls and lipoteichoic acids; LysS 
– lysine-tRNA-ligase; Cls1, Cls2 – synthesis of cardiolipids; YpfP – synthesis of 
diglucosyldiacylglycerol; LtaA – translocase of diglucosyldiacylglycerol; LtaS – 
synthesis of lipoteichoic acids) fused to the T25 fragment allowed to study 
interaction between two proteins. Where the two adenylate cyclase fragments 
fused to a functional complementation, colonies would appear blue indicating 
interaction between the two proteins (Fig. 9) [50]. 
 
Fig. 9: BACTH analysis of interactions between MprF and other proteins. Interaction is indicated by blue 
strains, no interaction appears white. After Kuhn et al. [50]. 
Interaction has been detected with DltD, YpfP, LtaA and LtaS [50].  
To investigate the previously obtained interactions more specifically, the 
flippase domain (aa 1-320) and the synthase domain (aa 328-840) respectively 
were fused to the T18 fragment. Another screening with the BACTH method 
was carried out. For both domains, this screening resulted in blue colonies for  
the glycolipid anchor synthase YpfP, the assumed LTA anchor flippase LtaA, 
the LTA synthase LtaS, and the D-alanine transferase DltD. This implies protein 
interaction of MprF with the LTA synthesis apparatus and with the LTA and 
WTA alanylation system (Fig. 10). 
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Fig. 10: BACTH analysis of interactions between the two domains of MprF and other proteins. Interaction is 
indicated blue, no interaction appears white. From Kuhn et al. [50]. 
3.2.2 Analysis of a connection between the DltABCD system and MprF in regards to 
daptomycin resistance 
MprF and dlt are both known to be hot spots for SNPs leading to DAP-R. To 
further elucidate the effects of the two resistance factors, DltABCD and MprF, 
undermentioned strains have been constructed. It should be determined how 
each protein by itself affects DAP-R. Furthermore, it should be explored how 
MprF and the DltABCD system in synergy affect DAP-R or hypersusceptibility to 
DAP, and whether the mprF point mutation T345A alters their interaction in 
some way. 
In a first step, in addition to the previously described constructed strains – with 
mprf knocked out and with pRB bearing mprF as WT or with the resistance 
SNP – dltA-knockout-mutations as well were supplied with those pRB variants 
via electroporation. Thus, the double knockout mutant of mprF and the dlt 
system has been compared to both the complementations with mprF and the 
DAP-R mutation T345A of mprF. Per agarose gel electrophoresis it was 
checked, whether the genes have been constructed successfully. Then the 
MICs of DAP and polymyxin B (PB) were determined via Etests. As expected, 
without mprF the non-susceptibility to DAP was decreased, and with the SNP 
T345A significantly increased compared to the WT. Without dltA, resistance to 
DAP was decreased and the resistance mutation in mprF showed an equally 
low tolerance level. Interestingly, without dltA the presence or absence of mprF 
seemed to have no relevance for tolerance of PB, and was consistently on a 
low level, even lower than when lacking only mprF (Fig. 11). 
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Fig. 11: MICs of DAP and PB (a, b) for ten strains of S. aureus SA113. The strains used were S. aureus SA113 
WT (1), ΔmprF (2), ΔmprF with pRB (3), ΔmprF with pRBmprF (4), ΔmprF with pRBmprF345 (5), ΔdltA (6), the 
double knockout ΔdltA ΔmprF (7), and the double knockout with pRB (8), pRBmprF (9), or pRBmprF345 (10), 
likewise. Biological replicates n = 6. P values of unpaired t tests are: a.1 vs. a.2 < 0,0001; a.1 vs. a.4 0,8187; 
a.1 vs. a.5 0,0006; a.1 vs. a.6 0,0005; a.6 vs. a.9 0,7191; a.6 vs. a.10 0,5925; b.1 vs. b.2 0,0002; b.1 vs. b.6 < 0,0001; 
b.2 vs. b.6 0,0001; b.6 vs. b.7 0.8040; b.6 vs. b.9 0,7342; b.6 vs. b.10 0,5155. 
In the second step, those variants of dltA knockout mutants were 
complemented via phage transduction with the plasmid pTX containing the dlt 
operon. The complemented dltA knockout and the complemented double 
knockout both showed approximately the same level of resistance to DAP as 
the WT. The dlt-complemented double knockout with the mprF345, however, 
showed neither WT level of resistance nor increased DAP-R but remained 
highly susceptible (Fig. 12). 
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Fig. 12:  MICs of DAP and PB (a, b) for 16 strains of S. aureus SA113. Biological replicates n = 4 for DAP and 
n = 2 for PB. Not depicted are the MICs of three other antibiotics (colistin,  linezolid, oxacillin) that were tested as 
well with four replicates and of two antibiotics (bacitracin, vancomycin) with two replicates. P values of t tests are: 
a.1 vs. a.5 0,0371; a.1 vs. a.10 < 0,0001; a.1 vs. a.11 0,0390; a.1 vs. a.14 0,3559; a.1 vs. 1.15 < 0,0001; 
a.1 vs. 1.16 < 0,0001; a.5 vs. a.16 0,0105;  a.10 vs. a.16 0,2070; a.15 vs. a.16 0,0390; b.1 vs. b.5 0,0377; 
b.1 vs. b.10 0,0001; b.1 vs. b.11 0,4226; b.1 vs. b.14 0,4226; b.1 vs. b.15 0,0001; b.1 vs. b.16 0,0034. 
This result suggests that the dlt operon cannot express its whole function when 
encoded on a plasmid, and might need other factors for full expression. 
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3.3 Membrane localisation of predicted peptide loops from MprF by 
insertion and detection of cysteine residues at a defined amino acid 
position 
3.3.1 Localisation of antibody binding sites to MprF 
To further examine the structure and function of MprF, especially of its flippase 
domain, a biochemical approach was used to localise the orientation of a 
certain peptide loop within the membrane.  
Maleimid is a highly specific marker for the amino acid cysteine. Hence, the 
extended loop – which was presumed to be flipping from cyto- to periplasmic 
and back again – was marked by exchanging an amino acid to a cysteine. In 
doing so, the amino acid to be substituted should be as similar to cysteine as 
possible, the charge and behaviour should be maintained, so that the exchange 
to cysteine would not alter the protein. Thus, out of different exchanges (T263C, 
V266C, P267C, L273C) proline 267 became the amino acid of choice (Fig. 13), 
as in the cysteine localisation assay it produced the strongest and clearest 
signals. So the other exchanges were not pursued. 
 
Fig. 13: Schematic figure of MprF with an amino acid exchange P267C in the putative loop. The naturally 
present cysteines (C199, C204, C217, C380, C526, C717) are depicted as well. Grey depicted is the lipid bilayer, 
green depicted is the flippase domain, beige depicted is the synthase domain, as yellow circles depicted are amino 
acids, C - cysteine, P - proline. 
Exchange was performed using site directed mutagenesis (see 2.3.4) within 
mprF inserted in the plasmid pT10. Initially, the strain used for cloning was 
E. coli, as it is easier to maintain and transform. 
Furthermore, cysteine is naturally found in MprF on amino acid positions 199, 
204 (on the extracellular side), 217, 380 (in transmembrane segments), 526 and 
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717 (on the intracellurlar side) (Fig. 13). To avoid detection of these cysteins, 
they also should have been exchanged to similar amino acids (C199S, C204S, 
C217A, C380A, C526S, C717S) (Fig. 14). Maleimid can only access the outer 
side of the intact cell membrane. However, during the labelling 
assay (see 2.7.3), the membrane is damaged and the cytoplasmic cysteines 
become accessible as well.  
The cysteine exchanges should have been performed out of precaution, so that 
they would not produce a polluting signal. 
Unfortunately, exchange of those naturally occurring cysteines, especially 
C717S, presented more difficult and time consuming. Thus, it was abandoned, 
as not all of them could be successfully exchanged within the scope of this 
work. 
 
Fig. 14: Schematic figure of MprF with P267C (in putative loop) and attempted but not succeeded exchanges 
of cysteine: C199S, C204S, C217A, C380A (in TMDs), C526S, C717S (intracellular). Grey depicted is the lipid 
bilayer, dark green depicted is the flippase domain, beige depicted is the synthase domain, as light green circles 
depicted are attempted but not succeeded amino acid exchanges, as yellow circle depicted is an amino acid, 
A - alanine, C - cysteine, P - proline, S - serine. 
To verify that the mutation P267C was successful DNA samples for sequencing 
were sent to GATC. Additionally, the MprF protein was provided with FLAG-tag, 
so that the MprF could later be extracted with magnetic FLAG beats and 
detected with an anti-FLAG-antibody. 
Preparing for the labelling assay, strain cultures were split in two halves and 
processed differently. For marking cysteine only on the outer surface, MBP was 
added and the reaction was quenched after a short time. In order to mark only 
intracellular cysteine, cysteine on the outer surface was blocked with AMS, cell 
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lysis was achieved with glass beads, so that the intracellular cysteine is 
exposed, and subsequently, MBP was added. 
For immunoprecipitation, magnetic FLAG beads were used, to separate MprF 
from cell debris. Via electrophoresis and Western Blot, the membrane proteins 
were transferred to a blot membrane (polyvinylidene fluoride). 
To detect and visualise MprF on the one hand, and the MPB labelled cysteine 
on the other hand, specific antibodies were applied. The antibodies used to 
index MprF were anti-FLAG (mouse) and anti-mouse 700 (with emission 
maxima of approximate 700 nm). For tracing the MPB marked cysteine in the 
putative flipping loop of MprF, a Streptavidin antibody (with emission maxima of 
approximate 800 nm) was added, which binds to MPB. 
Finally, antibody binding was measured with the Odyssey Imaging Systemof 
LI-COR (Lambda Instruments Corporation). 
The strains used for cloning were E. coli XL-10 gold ultra-competent cells 
harbouring versions of the FLAG-tagged plasmid pT10, namely (a) the empty 
plasmid, (b) pT10 with the original mprF, (c) pT10 bearing mprF marked with 
the amino acid change P267C, and (d) pT10 with mprF P267C and additionally 
the point mutation D731A disabling the synthase domain from LysPG synthesis 
as a control. For later analysis, S. aureus SA113 ΔmprF was used.  
For the strain with the “empty” pT10 plasmid, LI-COR analysis displayed no 
signal at 700 nm for MprF (more precisely for the anti-mouse-antibody binding 
to the anti-FLAG-antibody indicating the FLAG-tag of MprF), neither in the outer 
nor in the inner leaflet (see Fig. 15). The other three strains complemented with 
variants of mprF showed signals at 700 nm both on the peri- and the 
cytoplasmic side (see Fig. 15), thus, indicating presence of MprF. The bacteria 
containing pT10mprF had an additional signal at 800 nm indicating the 
presence of cysteine only on the inner side but not on the outer 
side (see Fig. 15). This is concordant with the current topology model of MprF, 
having no cysteine on the outer side but only in TMDs (C199, C204, C217) and 
on the inner side (C526, C717) (see Fig. 13). 
However, the strain with pT10mprFP267C showed a 800 nm signal on the inner 
as well as the outer side (see Fig. 15). This confirms that the loop of interest is 
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on the periplasmic side. Whether this loop is also on the cytoplasmic side 
cannot be deduced, as the signal maxima at 800 nm for the inner side could 
also originate from the original cytoplasmic cysteines (C526, C717).  
With the SNP D731A, which disables the synthase domain, there was no more 
indication of a cysteine at the outer side but only on the inner side. This 
suggests, that the loop with P267C, which has been detected at the outer side, 
is no more ot the outer side, implying it is on the inner the inner leaflet (Fig. 15). 
 
Fig. 15: Western blot of the single cysteine labelling assay. Left: Showing, the signals of 700 nm (anti-mouse 
binding to anti-FLAG binding to FLAG) showing the presence of MprF, and of 800 nm (streptavidin coupling to 
MPB coupling to cysteine) showing the marked loop of interest for the periplasmic (upper two) and cytoplasmic 
(lower two) side. Right: Overlay of the signals for MprF (indicated red) and the loop of interest (indicated green) for 
the periplasmic (upper) and cytoplasmic (lower) side. A - alanine, C - cysteine, D - aspartic acid, P - proline. 
The fact that the position of the extended loop – whether on the inner or on the 
outer side – depends on the presence of a substrate implies a flipping function 
as in the absence of LysPG there is no detection of the loop on the outer side or 
as to say no flipping of the loop to the periplasmic side.  
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4 Discussion 
MprF is known to be a major bacterial virulence factor that possesses the 
function of a LysPG synthase and is important for resistance against many 
CAMPs and CAMP-like antibiotics. The resistance is assumed to be based on 
an increased positive net charge of the bacterial cell surface. Furthermore, 
additionally to that so to say basic resistance, SNPs in mprF lead to increased 
tolerance or resistance to daptomycin without cross-resistance to other 
antibiotics. Whereupon the mechanism of this additional resistance is based on 
remains not clear. MprF is a flippase transferring the synthesised LysPG from 
the inner to the outer lipid leaflet. The exact transfer mechanism is not yet clear. 
Interestingly, most of the mutations enhancing resistance are located in the 
transient area from the synthase to the flippase domain in or near an extended 
loop, which is thought to be essential for the flipping mechanism. 
In this work it could be confirmed that mprF is indeed a potent resistance factor 
against CAMPs and that modification of DAP binding to the cell surface plays a 
vital role in its mechanism. Furthermore, it could be revealed that enhanced 
resistance to DAP through a specific SNP within mprF (T345A) is not due to 
less binding and more repulsion of DAP, as so far supposed. In contrast, it 
might possibly rely on the altered interaction between DAP and PG as a result 
of increased L-PG and decreased PG content of the bacterial membrane [11, 
61, 83]. In addition, the results show that both domains of MprF physically 
interact with other proteins of the LTA synthesis machinery and with the teichoic 
acid D-alanylation apparatus [50]. Of note, when deprived of the DltABCD 
system, MprF seems to be insufficient to confer resistance on its own against 
polymyxin B. However, no distinct connection could be detected between the 
interaction of MprF with the DltABCD system and DAP. Furthermore, the 
topology and function of MprF has been explored in more detail via a cysteine 
labelling assay. We provide evidence that the extended cytoplasmic loop 
(aa 245-298) of the flippase domain can flip to the outer side only when the 
synthase domain is intact. Therefore this loop is supposedly dependent on the 
presence of its substrate LysPG. 
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Moreover, the originally contained cysteines of MprF will also be exchanged to 
other amino acids to improve the quality of the signal outcome of the cysteine 
assay. Again, the properties of the amino acids have to be taken into account. 
Needless to say, the function of the mutated MprF has to be verified by 
measuring the levels of resistance via Etest MICs of DAP and other antibiotics. 
Our results help to understand the exact mechanism of how MprF operates and 
contributes to bacterial resistance against CAMPs and CAMP-like antibiotics. 
Our finding that the flipping loop is probably essential and therefore may 
represent the active center of the flippase, could deliver a target for a new class 
of therapeutic agents. These agents will not be antibiotics in a classical sense of 
being bacteriostatic or bactericidal but rather supporting known antibiotics. Their 
support might potentially be based on impeding bacterial resistance 
mechanisms, for instance antibodies binding to the flipping loop, inactivating its 
function, and thereby restoring the susceptibility of the cell to antibiotics or the 
human innate immune system. 
During this work, several difficulties, bottlenecks and some possible sources of 
error have been encountered. It became very apparent that, although using the 
same medium type (e. g. MHB or LB) with the same ingredients and recipes, 
growth of bacterial cultures and MIC analyses can show very different results 
when different providers (e. g. Roth, BD, Sigma-Aldrich) or even batches are 
used. Therefore, to ensure the reproducibility of data it has especially been 
seen to that medium and other materials (e. g. Etest stripes) were used from 
only one label and, when possible, from only one batch for one experimental 
setup. For future research, the single cysteine detection assay could be further 
improved. One aspect is suitability of the internal control. Here, only at the 
beginning of the experimental setup the OD600 was measured and adjusted. For 
better comparability of the final signals, adjustments could be integrated also at 
a later point. Another topic is protein degradation causing multiple bands in the 
Western Blot. It might be that this problem could already be solved by 
performing the experiment in S. aureus, which is the natural host for MprF 
rather than E. coli. 
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5 Abstract / Zusammenfassung 
Abstract 
An important virulence factor for bacterial pathogenicity is the Multiple Peptide 
Resistance Factor (MprF). This membrane protein produces the positively 
charged phospholipid lysyl phosphatidylglycerol (LysPG) that confers bacterial 
resistance against cationic antimicrobial peptides (CAMPs), CAMP-like 
antibiotics and the human immune system. 
This work served to better clarify MprF’s role in interaction with other proteins of 
the synthesis apparatus for membrane lipids. Furthermore, the function of MprF 
should be examined more in detail to possibly find new potential targets for 
antivirulent therapeutics. Such inhibitors, in contrast to antibiotics, could make 
bacterial pathogens more vulnerable for our immune system and therefore 
provide an alternative therapeutic option. 
Three aspects of MprF were looked into. 
For one thing, resistance conferred by mprF and mprFT345A was compared. It 
could be shown that the enhanced tolerance of S. aureus to DAP via MprF is 
not based on less binding of DAP, which implies that this is not due to an 
increased charge repulsion. Additionally, the often described SNP T345A in the 
ORF of mprF leading to increased resistance to DAP appeared to cause no 
change in the amount of cell-bound DAP. This suggests that – besides the 
known basic resistance against CAMPs and CAMP-like antibiotics via charge 
repulsion – there is another resistance mechanism which is conferred by 
T345A, specifically against DAP without cross-resistance, and is supposedly 
mediating alterations of how DAP and the cell surface with less PG interact.  
For another thing, assumed interactions between dlt and mprF were looked into. 
It could be shown that MprF and both its sub-domains interact with other 
proteins of the lipoteichoic acid (LTA) synthesis machinery and the 
D-alanylation pathway, namely YpfP, LtaA, LtaS and DltD. Interestingly, when 
dlt was knocked out and therefore the DltABCD system was not at hand, which 
is the synthesis apparatus for LTAs as membrane lipids, MprF alone was not 
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able to confer resistance to polymyxin B. This implies some kind of dependence 
between the function of MprF and the presence of LTAs. 
Thirdly, the topology and function of MprF has been investigated in more detail. 
At a defined amino acid position within a predicted loop of MprF, cysteine 
residues were inserted. By detecting these cysteine residues, the localisation of 
the loop in the membrane could be deduced. The extended cytoplasmic loop 
(aa 245-298) of the flippase domain could be detected on the outer side of the 
membrane. But when disabling the synthase domain via SNP D731A, a signal 
on the outer side of the layer could not be detected any more. This implies, 
firstly, that the aforementioned loop (aa 245-298) flips from the inner to the 
outer side of the membrane and, secondly, that this flipping occurs only as long 
as the synthase domain of MprF is intact, suggesting a dependence between 
the flipping of the extended loop and the presence of the substrate LysPG. 




Ein wichtiger Virulenzfaktor für bakterielle Pathogenität ist der Multiple Peptide 
Resistance Factor (MprF). Dieses Membranprotein stellt das positiv geladene 
Phospholipid Lysyl-Phosphatidylglycerol (LysPG) her, das bakterielle Resistenz 
gegen kationische antimikrobielle Peptide (KAMPs), KAMP-ähnliche Antibiotika 
und das humane Immunsystem verleiht.  
Diese Arbeit diente zur besseren Einordnung der Rolle MprFs in der Interaktion 
mit anderen Proteinen der Synthesemaschinerie von Membranlipiden. Zudem 
soll die Funktion von MprF näher untersucht werden, um eventuell neue 
potenzielle Ziele für antivirulente Therapeutika zu finden. Solche Inhibitoren 
könnten, im Gegensatz zu Antibiotika, die bekannt dafür sind, durch 
Selektionsdruck einen Vorteil zu erhalten, bakterielle Pathogene angreifbarer 
für unser Immunsystem machen und dadurch alternative Therapieoptionen 
liefern. 
Drei Aspekte von MprF wurden untersucht. 
Erstens wurde die Resistenz verglichen, welche durch mprF und mprFT345A 
gewährt wird. Es konnte gezeigt werden, dass die gesteigerte Duldung von 
DAP durch S. aureus mittels MprFs nicht auf einer geringeren Bindung von 
DAP basiert, was impliziert, dass es nicht auf verstärkter Ladungsabstoßung 
beruht. Zusätzlich schien eine oft beschriebene SNP (T345A) im ORF von 
mprF, welche zu erhöhter Resistenz gegen DAP führt, ebenso keine Änderung 
der Menge an zellgebundenem DAP zu zeigen. Dies deutet darauf hin, dass es 
– neben der bekannten Basisresistenz gegen KAMPs und KAMP-artige 
Antibiotika durch Ladungsabstoßung – einen weiteren Resistenzmechanismus 
gibt, der auf T345A beruht, spezifisch gegen Daptomycin und ohne 
Kreuzresistenz wirkt, und dass er vermutlich Änderungen vermittelt, wie DAP 
und die Zelloberfläche, die weniger PG enthält, interagieren.  
Zweitens wurden vermutete Interaktionen zwischen dlt und mprF untersucht. Es 
konnte gezeigt werden, dass MprF und seine beiden Sub-Domänen mit 
anderen Proteinen der LTA-Synthesemaschinerie und der D-Alanylierungsbahn 
interagieren, nämlich YpfP, LtaA, LtaS und DltD. Wenn dlt abgeschalten war 
und daher kein DltABCD-System bestand, welches der Syntheseapparat für 
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LTAs und Membranlipide ist, war interessanterweise MprF eigenständig nicht in 
der Lage, eine Resistenz gegen Polymyxin B zu gewähren. Dies impliziert eine 
Art von Abhängigkeit zwischen der Funktion von MprF und der Gegenwart von 
LTAs. 
Drittens wurden die Topologie und die Funktion von MprF detaillierter 
untersucht. indem es mit Cysteinresten markiert und selbige detektiert worden 
sind. An einer definierten Aminosäureposition innerhalb einer vorhergesagten 
Schleife von MprF wurden Cystein-Reste eingefügt. Indem diese Cystein-Reste 
detektiert wurden, konnte die Lokalisation der Schleife in der Membran 
abgeleitet werden. Die erweiterte zytoplasmatische Schleife (AS 245-298) der 
Flippasedomäne konnte an der äußeren Seite der Membran nachgewiesen 
werden. Jedoch, als die Synthasedomäne durch die SNP D731A deaktiviert 
wurde, konnte an der äußeren Seite der Membranschicht kein Signal mehr 
detektiert werden. Dies impliziert erstens, dass die oben genannte Schleife 
(AS 245-298) von der inneren an die äußere Seite der Membran flippt, und 
zweitens, dass dieses Flipping sich nur dann ereignet, wenn die 
Synthasedomäne von MprF intakt ist, was eine Abhägigkeit nahelegt zwischen 
dem Flipping der erweiterten Schleife und der Gegenwart des Substrates 
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angeboten hat, sowohl im Labor als auch als Korrekturleserin. 
Mein Dank gilt ebenso dem restlichen Lipids Team und natürlich auch der 
gesamten AG Peschel für eine umfassende Unterstützung, sei es bei 
Nährmedien, mit Chemikalien, bei Protokollen oder beim Aufräumen des einen 
oder anderen Malheurs, und die unschlagbar angenehme Arbeitsatmosphäre. 
 
Nicht zuletzt möchte ich meiner Familie danken. Meinen Eltern, die mir zwar 
nicht im Labor und bei der Arbeit geholfen haben, dafür jedoch alles andere 
drum herum ermöglicht haben. Meinem Bruder, der mich mit Witz und mit 
Laborerfahrung über manchen Frust hinweg unterstützt und ermuntert hat. 
Meinem Opa, der mich hin und wieder daran erinnert hat, das Wesentliche nicht 
aus den Augen zu verlieren. 
Óma, csillagod tényleg kis doctor.  
